Neurogene Inc (NGNE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Neurogene Inc (NGNE) has a cash flow conversion efficiency ratio of -0.110x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-26.12 Million) by net assets ($237.78 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Neurogene Inc (NGNE) balance sheet quality index to measure how much of total assets are equity-financed.
Neurogene Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Neurogene Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Neurogene Inc earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Neurogene Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Neurogene Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guangdong Mingzhu Group Co Ltd
SHG:600382
|
0.035x |
|
JINXIN FERT.GRP HD-00001
F:3NX
|
N/A |
|
Mengtian Home Group Inc.
SHG:603216
|
N/A |
|
Henan Ancai Hi-tech Co Ltd
SHG:600207
|
-0.033x |
|
Oculis Holding AG Ordinary shares
NASDAQ:OCS
|
-0.081x |
|
Yabao Pharmaceutical Group Co Ltd
SHG:600351
|
0.047x |
|
Jana Small Finance Bank
NSE:JSFB
|
-0.575x |
|
Shenzhen Absen Optoelectronic Co Ltd
SHE:300389
|
0.210x |
Annual Cash Flow Conversion Efficiency for Neurogene Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Neurogene Inc from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see Neurogene Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $264.89 Million | $-77.17 Million | -0.291x | -28.08% |
| 2024-12-31 | $310.38 Million | $-70.60 Million | -0.227x | +17.71% |
| 2023-12-31 | $186.02 Million | $-51.42 Million | -0.276x | +48.39% |
| 2022-12-31 | $98.63 Million | $-52.82 Million | -0.536x | -206.05% |
| 2021-12-31 | $-91.88 Million | $-46.40 Million | 0.505x | +492.96% |
| 2020-12-31 | $191.22 Million | $-24.57 Million | -0.129x | -18.29% |
| 2019-12-31 | $141.69 Million | $-15.39 Million | -0.109x | +75.00% |
| 2018-12-31 | $72.67 Million | $-31.58 Million | -0.435x | +3.91% |
| 2017-12-31 | $98.89 Million | $-44.72 Million | -0.452x | -116.43% |
| 2016-12-31 | $144.66 Million | $-30.23 Million | -0.209x | -11.77% |
| 2015-12-31 | $108.42 Million | $-20.27 Million | -0.187x | +62.05% |
| 2014-12-31 | $36.15 Million | $-17.81 Million | -0.493x | -218.24% |
| 2013-12-31 | $51.28 Million | $-7.94 Million | -0.155x | +98.13% |
| 2012-12-31 | $874.03K | $-7.23 Million | -8.275x | -625.11% |
| 2011-12-31 | $8.59 Million | $-9.80 Million | -1.141x | -- |
About Neurogene Inc
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disea… Read more